Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally. It serves consumers through its AI-driven online platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty, wellness, and technology products. The company provides a portfolio of products, including face and complexion, eye, brow and lip products, makeup tools, skincare, haircare, and supplements under the IL MAKIAGE and SpoiledChild brands. In addition, it operates ODDITY LABS, a biotechnology center, which deploys AI-based molecule discovery technology to identify and launch novel ingredients that delivers performance and outcomes for consumers in beauty and wellness. Oddity Tech Ltd. was incorporated in 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD – Research Report) and Resmed (RMD – R...

Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Resmed (RMD)

In a report released today, Cory Carpenter from J.P. Morgan maintained a Buy rating on ODDITY Tech Ltd. Class A, with a price target of $59.00. Acc...

J.P. Morgan Reaffirms Their Buy Rating on ODDITY Tech Ltd. Class A (ODD)

Growth stocks reflect firms on track for swift expansion, beating peers and the overall market. Their strategy to reinvest profits drives continued...

3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 12/8/2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioAge Labs, Inc. (BIOA – Research Report) and Ins...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (BIOA) and Insulet (PODD)

In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet, with a price target of $370.00. Wood covers the He...

Morgan Stanley Keeps Their Buy Rating on Insulet (PODD)

In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Insulet, with a price target of $412.00. Newitter cov...

Insulet (PODD) Gets a Buy from Truist Financial

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Insulet yesterday and set a price target of $380.00. The company’s shares closed...

RBC Capital Remains a Buy on Insulet (PODD)

ODDITY Tech Ltd. Class A ( ($ODD) ) has released its Q3 earnings. Here is a breakdown of the information ODDITY Tech Ltd. Class A presented to its ...

ODDITY Tech Reports Record Earnings and Raises Outlook

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on ODDITY Tech Ltd. Class A (ODD – Research Report) and...

Analysts Offer Insights on Technology Companies: ODDITY Tech Ltd. Class A (ODD) and JetAI (JTAI)

An update from ODDITY Tech Ltd. Class A ( ($ODD) ) is now available. On November 19, 2025, ODDITY Tech Ltd. announced its financial results for the...

ODDITY Tech Reports Record Q3 Results and Launches METHODIQ

ODDITY Tech Ltd. Class A ( ($ODD) ) just unveiled an update. On November 18, 2025, ODDITY Tech Ltd. announced the launch of METHODIQ, a telehealth ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ODD	$43.82	-1.40%	684.57K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ODD	$43.82	-1.4%	684.57K
3
4
5
6

ODD

ODD

Dividend Overview

Get ODDITY Tech Ltd. Data in Excel

Get ODDITY Tech Ltd. Data in Excel